1711P Real-world study of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal tumors

The NCCN guidelines recommend that long-acting G-CSF be administered on days 2-4 after chemotherapy to prevent neutropenia. This study investigated the incidence of grade 3/4 neutropenia in patients (pts) with gastrointestinal tumors after administration of mecapegfilgrastim (a long-acting G-CSF) in a real-world setting.